Our study demonstrated that Tongxinluo, as an adjunctive therapy, significantly improved overall efficacy, NIHSS score, TC, hs-CRP, LDL, HDL, TNF-α, IL-6, high-shear whole blood viscosity, low-shear whole blood viscosity, Barthel index score, plaque area, MMSE score, FM score, plasma viscosity, plasma fibrinogen, red blood cell volume, NO, and quality of life index in stroke patients. This evidence concerns the gene CRP and stroke disorder.